ClinicalTrials.gg
CompletedNCT03072719Updated Mar 6, 2018Results posted

The Efficacy of a Dentifrice in Providing Relief From Immediate and Short Term Relief From Dentinal Hypersensitivity

A Phase 3 interventional study of Stannous Fluoride and Sodium Monofluorophosphate in Dentine Hypersensitivity, sponsored by GlaxoSmithKline. Completed at 1 site in Ireland. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-03-06.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years after the study started (first participant enrolled Mar 2012, registered Mar 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies in Dentin Sensitivity by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Dentin Sensitivity · GlaxoSmithKline.

Enrollment
20th of 28
120 · median 164
Started
2012
with 3 others
Phase 3
5 of 28
none open now
Registered
24th of 28
by date

Among the 28 studies in Dentin Sensitivity by GlaxoSmithKline, this one is the 20th largest by enrollment, is one of 4 that started in 2012, is one of 5 in phase 3, and was the 24th registered.

Dentin Sensitivity

290 studies on the registry are indexed under Dentin Sensitivity; 48 are open to participants now.

Browse Dentin Sensitivity studies →

Open to participants now

None of the 28 studies in Dentin Sensitivity by GlaxoSmithKline is open now. The open studies under Dentin Sensitivity, anywhere →

Who these studies take

Of the 19 Dentin Sensitivity studies recruiting now, 6 (32%) set no upper age limit and 12 (63%) stop at 75 or younger; 1 takes children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 28 studies in Dentin Sensitivity by GlaxoSmithKline as a file.
02

Study summary

A randomised, examiner blind, two treatment arm, stratified, parallel design, single-site study in subjects with at least two sensitive teeth to compare the efficacy of a test dentifrice against that of a control dentifrice in reducing dentinal hypersensitivity.

03

Conditions studied

  • Dentine Hypersensitivity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Demonstrates understanding of the study and willingness to participate
  • Aged at least 18 to 65 years
  • Understands and is willing, able and likely to comply with all study procedures and restrictions
  • Good general health with (in the opinion of the investigator) no and relevant abnormalities of medical history or oral examination.
  • Self-reported history of dentinal lasting more than 6 months but not more than 10 years
  • Minimum of 20 natural teeth at screening, a minimum of two accessible teeth (incisors, canines, pre-molars)
  • At baseline, participant has two non-adjacent sensitive teeth from those meeting the EAR, GI and mobility criteria at screening, with sensitivity measured by tactile stimulus (Yeaple ≤ 20g) and evaporative (air) assessment (Schiff Sensitivity Score ≥ 2) at baseline

Exclusion criteria

Exclusion

  • Pregnant or breast-feeding women
  • Known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients.
  • Participation in another clinical study or receipt of an drug within 30 days of the screening visit
  • Recent history (within the last year) of alcohol or other substance abuse
  • An employee of the sponsor or the study site or members of their immediate family
  • Presence of chronic debilitating disease which, in the opinion of the investigator, could affect study outcomes.
  • Any condition which, in the opinion of the investigator, causes xerostomia
  • Dental prophylaxis within 4 weeks of screening
  • Tongue or lip piercing or presence of dental implants
  • Professional desensitising treatment within 12 weeks of screening
  • Gross periodontal disease, treatment of periodontal disease (including surgery) within 12 months of screening, scaling or root planning within 3 months of screening.
  • Teeth bleaching within 12 weeks of screening
  • Tooth with evidence of current or recent caries, or reported treatment of decay in 12 months of screening
  • Tooth with exposed dentine but with deep, defective or facial restorations, teeth used as abutments for fixed or removable partial dentures, teeth with full crowns or veneers, orthodontic bands or cracked enamel. Sensitive teeth with contributing aetiologies other than erosion, abrasion or recession of exposed dentine
  • Sensitive tooth not expected to respond to treatment with an over-the counter dentifrice in the opinion of the investigator.
  • Use of a desensitising dentifrice within six weeks of screening (participant will be required to bring their current dentifrice to the site in order to verify the lack of known anti-sensitivity ingredients)
  • Daily doses of a medication which, in the opinion of the investigator, could interfere with the perception of pain
  • Currently taking antibiotics or have taken antibiotics within 2 weeks of baseline.
  • Daily doses of a medication which, in the opinion of the investigator, causes xerostomia
  • Individuals who require antibiotic prophylaxis for dental procedures
  • Any participant who, in the judgment of the investigator, should not participate in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Dentifrice containing stannous fluoride

    Toothpaste

    Drug: Stannous Fluoride

  • Active comparator
    Dentifrice containing Sodium Monofluorophosphate

    Toothpaste

    Drug: Sodium Monofluorophosphate

Interventions

  • Test dentifrice, participants will brush each of the 2 selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute.

  • Control dentifrice, participants will brush the whole mouth thoroughly for at least 1 minute.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Schiff Sensitivity Score on Day 14

    Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicates improvement in sensitivity.

    Time frame: Baseline, Day 14

Secondary outcomes

  1. Change From Baseline in Schiff Sensitivity Score on Post First Brushing (After 5 Minutes) and Day 3

    Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicate improvement in sensitivity.

    Time frame: Baseline, post first brushing (after 5 minutes) and Day 3

  2. Change From Baseline in Tactile (Yeaple) Pain Threshold on Post First Brushing (After 5 Minutes), Day 3 and Day 14

    Tactile threshold was assessed by examiner using a constant pressure probe (Yeaple probe) which allowed application of a known force to the dentin surface from 10 g to an upper threshold of 80g in increments of 10 g. The tactile threshold is the maximum pressure applied at which participant do not report any pain or discomfort. The tactile threshold for each tooth was determined by asking the participant whether the sensation caused discomfort. The pressure setting at which the participant gave two consecutive 'yes' responses was recorded as the tactile threshold. The higher the tactile threshold, the less sensitive the tooth.

    Time frame: Baseline, post first brushing (after 5 minutes), Day 3 and Day 14

07

Results

Posted Apr 18, 2017

Participant flow

Participants were recruited at a single center in Ireland.

Participant flow — Overall Study
MilestoneExperimental DentifriceReference Dentifrice
Started6060
Completed5959
Not completed11
Withdrew: Adverse event11

Outcome measures

PrimaryChange From Baseline in Schiff Sensitivity Score on Day 14

Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicates improvement in sensitivity.

Time frame:
Baseline, Day 14
Reported as:
Mean · score on a scale
Change From Baseline in Schiff Sensitivity Score on Day 14
score on a scaleExperimental DentifriceReference Dentifrice
At Baseline2.51 ± 0.4372.51 ± 0.446
At Day 141.16 ± 0.7741.35 ± 0.901
Change from Baseline on Day 14-1.35 ± 0.727-1.16 ± 0.762
Statistical analysis
  • Experimental Dentifrice vs Reference Dentifrice · ANCOVA · p = 0.1774 (From ANCOVA model: Treatment as fixed factor, baseline Schiff Sensitivity score as covariate.) · Least square (ls) mean difference: -0.19 · 95% CI -0.46 to 0.09Difference is 0.454% stannous fluoride minus 0.76% sodium monofluorophosphate such that a negative difference favours first named treatment.
SecondaryChange From Baseline in Schiff Sensitivity Score on Post First Brushing (After 5 Minutes) and Day 3

Schiff sensitivity score was assessed by examiner as participant's response to an evaporative (air) stimulus after the stimulation of each individual tooth. Response of participant was scored using Schiff sensitivity scale range of 0-3; 0=Participant does not respond to air stimulation; 1=Participant responds to air stimulus but does not request discontinuation of stimulus; 2=Participant responds to air stimulus and requests discontinuation or moves from stimulus; 3= Participant responds to stimulus, considers stimulus to be painful, and requests discontinuation of the stimulus. A reduction in Schiff Sensitivity score indicate improvement in sensitivity.

Time frame:
Baseline, post first brushing (after 5 minutes) and Day 3
Reported as:
Mean · score on a scale
Change From Baseline in Schiff Sensitivity Score on Post First Brushing (After 5 Minutes) and Day 3
score on a scaleExperimental DentifriceReference Dentifrice
After 5 minutes of brushing1.73 ± 0.8261.92 ± 0.737
Change after 5 minutes of brushing-0.78 ± 0.660-0.59 ± 0.571
On Day 31.63 ± 0.7841.77 ± 0.785
Change from baseline on Day 3-0.88 ± 0.658-0.74 ± 0.568
SecondaryChange From Baseline in Tactile (Yeaple) Pain Threshold on Post First Brushing (After 5 Minutes), Day 3 and Day 14

Tactile threshold was assessed by examiner using a constant pressure probe (Yeaple probe) which allowed application of a known force to the dentin surface from 10 g to an upper threshold of 80g in increments of 10 g. The tactile threshold is the maximum pressure applied at which participant do not report any pain or discomfort. The tactile threshold for each tooth was determined by asking the participant whether the sensation caused discomfort. The pressure setting at which the participant gave two consecutive 'yes' responses was recorded as the tactile threshold. The higher the tactile threshold, the less sensitive the tooth.

Time frame:
Baseline, post first brushing (after 5 minutes), Day 3 and Day 14
Reported as:
Mean · gram (g)
Change From Baseline in Tactile (Yeaple) Pain Threshold on Post First Brushing (After 5 Minutes), Day 3 and Day 14
gram (g)Experimental DentifriceReference Dentifrice
At Baseline10.8 ± 2.2911.5 ± 2.65
After 5 minutes of brushing16.5 ± 13.8216.7 ± 11.19
Change after 5 minutes of brushing5.7 ± 13.455.2 ± 10.93
On Day 318.4 ± 17.3218.6 ± 16.73
Change from baseline on Day 37.5 ± 17.737.1 ± 16.48
On Day 1425.3 ± 22.6423.8 ± 22.33
Change from baseline on Day 1414.6 ± 22.6712.3 ± 21.68

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental Dentifrice0/60 (0%)0/60 (0%)9/60 (15%)
Reference Dentifrice0/60 (0%)0/60 (0%)8/60 (13.3%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventExperimental DentifriceReference Dentifrice
Sensitivity of TeethGastrointestinal disorders5/600/60
Dry MouthGastrointestinal disorders0/602/60
Gingival BleedingGastrointestinal disorders0/601/60
GingivitisGastrointestinal disorders1/600/60
Mouth UlcerationGastrointestinal disorders0/601/60
Oral HerpesInfections and infestations0/601/60
Tooth InjuryInjury, poisoning and procedural complications1/600/60
ToothacheGastrointestinal disorders1/600/60
Axillary CandidiasisInfections and infestations1/600/60
Axillary PainGeneral disorders1/600/60

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Experimental DentifriceReference DentifriceTotal
Mean28.4 ± 12.8530.7 ± 11.6629.5 ± 12.27
Sex: Female, Male
Sex: Female, Male(Participants)Experimental DentifriceReference DentifriceTotal
Female354075
Male252045
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Experimental DentifriceReference DentifriceTotal
Hispanic or Latino112
Not Hispanic or Latino5959118
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental DentifriceReference DentifriceTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White6059119
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • GSK Investigational Site
    Cork, Ireland
09

References and documents

Publications

  • Parkinson CR, Hughes N, Hall C, Whelton H, Gallob J, Mason S. Three randomized clinical trials to assess the short-term efficacy of anhydrous 0.454% w/w stannous fluoride dentifrices for the relief of dentin hypersensitivity. Am J Dent. 2016 Feb;29(1):25-32. PubMed 27093773 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2012 to primary completion in Jun 2012, 3 months.

Results were first posted in Apr 2017, 4 years 10 months after primary completion.

Of 13 phase 3 interventional studies under Dentin Sensitivity, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2017
First posted
Mar 7, 2017
StartActual
Mar 1, 2012
Primary completionActual
Jun 1, 2012
CompletionActual
Jun 12, 2012
Results first posted
Apr 18, 2017
Last update
Mar 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03072719
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 7, 2017
Start date
Mar 1, 2012
Primary completion
Jun 1, 2012
Completion
Jun 12, 2012
Results posted
Apr 18, 2017
Last update
Mar 6, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tin Fluorides

Start the discussion